ORIC Pharmaceuticals Competitors

ORIC Pharmaceuticals (NASDAQ:ORIC) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Valuation & Earnings

This table compares ORIC Pharmaceuticals and Taro Pharmaceutical Industries' gross revenue, earnings per share and valuation.

Taro Pharmaceutical Industries has higher revenue and earnings than ORIC Pharmaceuticals.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ORIC Pharmaceuticals and Taro Pharmaceutical Industries, as provided by MarketBeat.com.

ORIC Pharmaceuticals presently has a consensus price target of $43.7143, suggesting a potential upside of 122.01%. Taro Pharmaceutical Industries has a consensus price target of $81.00, suggesting a potential upside of 11.59%. Given ORIC Pharmaceuticals' higher possible upside, equities research analysts plainly believe ORIC Pharmaceuticals is more favorable than Taro Pharmaceutical Industries.

Insider & Institutional Ownership

73.4% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares ORIC Pharmaceuticals and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Summary

Taro Pharmaceutical Industries beats ORIC Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

ORIC Pharmaceuticals (NASDAQ:ORIC) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Valuation & Earnings

This table compares ORIC Pharmaceuticals and OPKO Health's gross revenue, earnings per share and valuation.

ORIC Pharmaceuticals has higher earnings, but lower revenue than OPKO Health.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ORIC Pharmaceuticals and OPKO Health, as provided by MarketBeat.com.

ORIC Pharmaceuticals presently has a consensus price target of $43.7143, suggesting a potential upside of 122.01%. OPKO Health has a consensus price target of $9.00, suggesting a potential upside of 121.67%. Given ORIC Pharmaceuticals' higher possible upside, equities research analysts plainly believe ORIC Pharmaceuticals is more favorable than OPKO Health.

Insider & Institutional Ownership

73.4% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 28.5% of OPKO Health shares are held by institutional investors. 40.9% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares ORIC Pharmaceuticals and OPKO Health's net margins, return on equity and return on assets.

Summary

ORIC Pharmaceuticals beats OPKO Health on 6 of the 9 factors compared between the two stocks.

ORIC Pharmaceuticals (NASDAQ:ORIC) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Profitability

This table compares ORIC Pharmaceuticals and Corcept Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ORIC Pharmaceuticals and Corcept Therapeutics, as provided by MarketBeat.com.

ORIC Pharmaceuticals presently has a consensus price target of $43.7143, suggesting a potential upside of 122.01%. Corcept Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 7.00%. Given ORIC Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe ORIC Pharmaceuticals is more favorable than Corcept Therapeutics.

Insider & Institutional Ownership

73.4% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 75.4% of Corcept Therapeutics shares are held by institutional investors. 16.4% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares ORIC Pharmaceuticals and Corcept Therapeutics' gross revenue, earnings per share and valuation.

Corcept Therapeutics has higher revenue and earnings than ORIC Pharmaceuticals.

Summary

Corcept Therapeutics beats ORIC Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Intra-Cellular Therapies (NASDAQ:ITCI) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares Intra-Cellular Therapies and ORIC Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Intra-Cellular Therapies and ORIC Pharmaceuticals, as provided by MarketBeat.

Intra-Cellular Therapies presently has a consensus price target of $47.4286, suggesting a potential upside of 49.57%. ORIC Pharmaceuticals has a consensus price target of $43.7143, suggesting a potential upside of 122.01%. Given ORIC Pharmaceuticals' higher possible upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Intra-Cellular Therapies.

Insider and Institutional Ownership

79.1% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 73.4% of ORIC Pharmaceuticals shares are held by institutional investors. 18.2% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Intra-Cellular Therapies and ORIC Pharmaceuticals' gross revenue, earnings per share and valuation.

ORIC Pharmaceuticals has lower revenue, but higher earnings than Intra-Cellular Therapies.

Summary

Intra-Cellular Therapies beats ORIC Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Deciphera Pharmaceuticals (NASDAQ:DCPH) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares Deciphera Pharmaceuticals and ORIC Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Deciphera Pharmaceuticals and ORIC Pharmaceuticals, as provided by MarketBeat.

Deciphera Pharmaceuticals presently has a consensus price target of $70.30, suggesting a potential upside of 59.59%. ORIC Pharmaceuticals has a consensus price target of $43.7143, suggesting a potential upside of 122.01%. Given ORIC Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Deciphera Pharmaceuticals.

Insider and Institutional Ownership

73.6% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 73.4% of ORIC Pharmaceuticals shares are held by institutional investors. 7.0% of Deciphera Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Deciphera Pharmaceuticals and ORIC Pharmaceuticals' gross revenue, earnings per share and valuation.

ORIC Pharmaceuticals has lower revenue, but higher earnings than Deciphera Pharmaceuticals.

Rocket Pharmaceuticals (NASDAQ:RCKT) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares Rocket Pharmaceuticals and ORIC Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Rocket Pharmaceuticals and ORIC Pharmaceuticals, as provided by MarketBeat.

Rocket Pharmaceuticals presently has a consensus price target of $59.1818, suggesting a potential upside of 44.45%. ORIC Pharmaceuticals has a consensus price target of $43.7143, suggesting a potential upside of 122.01%. Given ORIC Pharmaceuticals' higher possible upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Rocket Pharmaceuticals.

Insider and Institutional Ownership

73.4% of ORIC Pharmaceuticals shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and ORIC Pharmaceuticals' gross revenue, earnings per share and valuation.

Summary

ORIC Pharmaceuticals beats Rocket Pharmaceuticals on 4 of the 7 factors compared between the two stocks.